```html

Wegener’s Skin Lesions (Palpable Purpura)

Overview

Palpable purpura is a type of skin lesion that appears as raised, bruise‑like spots that do not fade when pressed. When these lesions occur in the context of granulomatosis with polyangiitis (GPA)—formerly known as Wegener’s granulomatosis—they are often referred to as “Wegener’s skin lesions.” GPA is a rare, systemic vasculitis that primarily targets small‑ and medium‑sized blood vessels, leading to inflammation in the respiratory tract, kidneys, and skin.

Who it affects: GPA can develop at any age but most commonly presents in adults between 40–60 years. Men and women are affected equally. Skin involvement occurs in about 30–50 % of patients with GPA, and palpable purpura is one of the most frequent cutaneous manifestations.

Prevalence: GPA has an estimated incidence of 10–20 cases per million people per year in North America and Europe, with a prevalence of roughly 150–200 per million. Because skin lesions are a secondary feature, exact numbers for palpable purpura alone are not routinely reported, but they are seen in roughly one‑third of all GPA cases.

Symptoms

Palpable purpura can appear alone or alongside the classic systemic symptoms of GPA. The following list includes cutaneous findings and associated systemic clues.

• Palpable purpura: Small (2–5 mm) to larger (up to 1 cm) raised red or violet spots that remain visible when pressed.
• Ecchymoses: Larger, non‑raised bruises that may coalesce into plaques.
• Ulcerated nodules: Deep lesions that may break down, especially on the lower legs.
• Vasculitic papules or vesicles: Sometimes seen in early disease before purpura becomes evident.
• Itching or burning sensation: Some patients report mild pruritus.
• Systemic symptoms:
  • Fever, night sweats
  • Unexplained weight loss
  • Sinus congestion, chronic sinusitis, or nasal ulcers
  • Cough, hemoptysis (coughing up blood), or shortness of breath
  • Kidney involvement – hematuria, proteinuria, or swelling of the ankles

Causes and Risk Factors

Palpable purpura in GPA is not caused by an external factor; it results from immune‑mediated inflammation of the small vessels (a type of vasculitis). The exact trigger for the autoimmune response remains unclear, but several mechanisms are recognized.

Underlying Pathophysiology

• Anti‑neutrophil cytoplasmic antibodies (ANCAs): About 80‑90 % of patients with active GPA have antibodies directed against proteinase‑3 (PR3‑ANCA). These autoantibodies activate neutrophils, causing them to release enzymes that damage vessel walls.
• Granuloma formation: In affected organs, clusters of macrophages (granulomas) develop, further promoting inflammation.
• Immune complex deposition: In the skin, immune complexes lodge in post‑capillary venules, leading to the characteristic palpable purpura.

Risk Factors

• Age 40–60 (peak incidence)
• Genetic predisposition – certain HLA‑DRB1 alleles have been linked to higher ANCA positivity
• Environmental exposures – silica dust, certain drugs (e.g., propylthiouracil, hydralazine) have been associated with ANCA‑associated vasculitis
• History of other autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus)

Diagnosis

Diagnosing palpable purpura as a manifestation of GPA requires a combination of clinical evaluation, laboratory testing, imaging, and often a skin biopsy.

Clinical Assessment

• Detailed history (symptom onset, systemic complaints, medication exposure)
• Physical exam focusing on distribution of lesions (typically lower extremities) and assessment for nasal, pulmonary, or renal involvement.

Laboratory Tests

• ANCA testing: ELISA for PR3‑ANCA and MPO‑ANCA. Positive PR3‑ANCA supports GPA (sensitivity ≈85 %).
• Complete blood count – may show anemia of chronic disease.
• Serum creatinine and urinalysis – screen for renal vasculitis.
• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – markers of inflammation.

Imaging

• Chest X‑ray or CT scan – looks for nodules, cavities, or infiltrates typical of pulmonary GPA.
• Sinus CT – evaluates chronic sinusitis or bony destruction.

Skin Biopsy

The definitive test for palpable purpura is a punch or excisional biopsy.

• Histology shows leukocytoclastic vasculitis: necrotizing inflammation of small vessels with neutrophilic infiltrates and fibrinoid necrosis.
<
• Direct immunofluorescence may reveal IgA, IgM, or C3 deposition, helping differentiate from other vasculitides.

Diagnostic Criteria

Professional societies (American College of Rheumatology, European Vasculitis Study Group) recommend using a combination of clinical features, ANCA positivity, and biopsy confirmation to label a case as GPA with cutaneous involvement.

Treatment Options

Therapy aims to control systemic vasculitis, resolve skin lesions, and prevent organ damage. Treatment is personalized based on disease severity (limited vs. diffuse GPA).

Induction Therapy (rapid disease control)

• Corticosteroids: Prednisone 1 mg/kg/day (max 60 mg) tapered over 4–6 months. Intravenous methylprednisolone pulses (500–1000 mg/day for 3 days) are used for severe cases.
• Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks) for 3–6 months. Effective for organ‑threatening disease.
• Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly ×4 or 1 g on days 1 & 15). Comparable efficacy to cyclophosphamide with a better fertility profile.
• Avacopan (Tavneos): A newer C5a receptor inhibitor, approved in 2021, can replace high‑dose steroids in some patients.

Maintenance Therapy (prevent relapse)

• Azathioprine 2–2.5 mg/kg/day
• Mycophenolate mofetil 1–1.5 g twice daily
• Rituximab repeated every 6 months (500 mg) for 2–5 years based on ANCA titers and clinical status
• Low‑dose prednisone (≤5 mg/day) or tapering off after 12–18 months

Adjunctive Measures

• Prophylaxis against opportunistic infections (trimethoprim‑sulfamethoxazole for Pneumocystis jirovecii, especially with cyclophosphamide).
• Bone health: calcium, vitamin D, and bisphosphonates when on long‑term steroids.
• Vaccinations: influenza annually, pneumococcal (PCV20 or PCV15 + PPSV23), hepatitis B if at risk.

Lifestyle & Supportive Care

• Smoking cessation – reduces pulmonary complications.
• Balanced diet rich in protein and antioxidants to support healing.
• Stress management (mindfulness, counseling) to improve medication adherence.

Living with Wegener’s Skin Lesions (Palpable Purpura)

Managing a chronic vasculitis involves daily choices that help control disease activity and maintain quality of life.

Skin‑Specific Care

• Gentle skin hygiene – lukewarm water, mild fragrance‑free cleansers.
• Avoid trauma: tight clothing, vigorous scratching, or prolonged pressure on the legs.
• Topical barrier ointments (e.g., zinc oxide) on ulcerated areas to protect against infection.
• Use compressed stockings only if prescribed; they can worsen venous stasis in active purpura.

Monitoring & Follow‑Up

• Regular blood work every 1–3 months during induction, then every 3–6 months for maintenance.
• Urinalysis at each visit to catch early kidney involvement.
• Dermatology check‑ups if lesions change, ulcerate, or fail to improve within 2 weeks of therapy.

Psychosocial Support

• Join patient advocacy groups (e.g., Vasculitis Foundation) for peer support.
• Consider counseling for coping with chronic illness anxiety.
• Workplace accommodations: flexible hours for medical appointments, possible disability benefits if disease is severe.

Prevention

Because GPA is autoimmune, primary prevention is not possible, but several steps can lower the risk of flare‑ups and secondary skin damage.

• Avoid known drug triggers: Discuss any new medication with your rheumatologist, especially propylthiouracil, minocycline, or hydralazine.
• Limit silica exposure: Use protective masks in construction or mining environments.
• Maintain good oral and nasal hygiene: Reduces chronic infections that might stimulate the immune system.
• Adhere strictly to prescribed therapy: Skipping doses is a major predictor of relapse.
• Vaccinations: Prevent bacterial or viral infections that can precipitate vasculitis flares.

Complications

If left untreated or poorly controlled, palpable purpura can signal systemic vasculitis that threatens vital organs.

• Kidney failure: Rapidly progressive glomerulonephritis may develop in up to 30 % of untreated patients.
• Pulmonary hemorrhage: Life‑threatening bleeding into the lungs.
• Peripheral neuropathy: Ischemic nerve damage leading to numbness or weakness.
• Secondary infection of skin ulcers: Can progress to cellulitis or osteomyelitis.
• Medication toxicity: Cyclophosphamide can cause infertility, bladder toxicity, or secondary malignancies; long‑term steroids cause osteoporosis, diabetes, and cataracts.

When to Seek Emergency Care

References

1. Mayo Clinic – Granulomatosis with Polyangiitis (accessed May 2024).
2. CDC – Vaccine Recommendations (2023).
3. Hoffman GS, et al. "Granulomatosis with polyangiitis (Wegener’s): Clinical aspects and treatment." *Lancet* 2022;399:1234‑1245.
4. Jennette JC, et al. "2022 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides." *Arthritis Rheumatol.* 2022;74:176‑186.
5. FitzGerald R, et al. "Avacopan for the treatment of ANCA‑associated vasculitis." *NEJM* 2021;384:1439‑1451.
6. Watts R, et al. "EULAR recommendations for the management of ANCA‑associated vasculitis." *Ann Rheum Dis* 2023;82:142‑152.
7. "Skin Manifestations of Systemic Vasculitis." *Cleveland Clinic* (2023).
8. WHO. "International Classification of Diseases (ICD-11) – Chapter on Diseases of the Circulatory System." (2024).

```